Breast cancer: implications of tumor cell kinetics on clinical outcome.

M. G. Daidone, R. Silvestrini, L. Ventura, C. Coltro Campi, B. Salvadori, C. Bartoli

Research output: Contribution to journalArticle

Abstract

The relevance of tumor proliferative activity as an indicator of biologic aggressiveness was analyzed on a series of 506 patients with primary breast cancer. In 258 patients with operable tumors without nodal and distant metastases, none of whom was subjected to postoperative irradiation or systemic adjuvant therapy, proliferative activity was significantly correlated with prognosis; 6-year relapse-free survival (RFS) and overall survival (OS) were higher for patients with slowly proliferating tumors for patient with fast-proliferating tumors (RFS: 80.5% vs 59.6%, p = 0.00004; OS: 90.8% vs 74.4%, p = 0.002). On a series of 196 patients with node-positive operable tumors, subjected to 6 or 12 cycles of cyclophosphamide, methotrexate and 5-fluorouracil, a trend in favor of longer 6-year RFS was observed for patients with slowly proliferating tumors than for patients with fast-proliferating tumors (62.5% vs 48.3%, p = 0.08), whereas proliferative activity did not influence OS. In 52 patients with locally advanced disease treated with a multimodality approach, including chemotherapy (adriamycin and vincristine), surgery or radiotherapy, tumor proliferative activity was a strong indicator of biologic aggressivity, since women with slowly proliferating cancers had a higher 4-year probability of OS than women with fast-proliferating tumors (68.1% vs 36.7%, p = 0.02).

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalBasic and Applied Histochemistry
Volume30
Issue number2
Publication statusPublished - 1986

Fingerprint

Breast Neoplasms
Neoplasms
Survival
Recurrence
Vincristine
Methotrexate
Fluorouracil
Doxorubicin
Cyclophosphamide
Radiotherapy
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Anatomy

Cite this

Daidone, M. G., Silvestrini, R., Ventura, L., Coltro Campi, C., Salvadori, B., & Bartoli, C. (1986). Breast cancer: implications of tumor cell kinetics on clinical outcome. Basic and Applied Histochemistry, 30(2), 221-226.

Breast cancer : implications of tumor cell kinetics on clinical outcome. / Daidone, M. G.; Silvestrini, R.; Ventura, L.; Coltro Campi, C.; Salvadori, B.; Bartoli, C.

In: Basic and Applied Histochemistry, Vol. 30, No. 2, 1986, p. 221-226.

Research output: Contribution to journalArticle

Daidone, MG, Silvestrini, R, Ventura, L, Coltro Campi, C, Salvadori, B & Bartoli, C 1986, 'Breast cancer: implications of tumor cell kinetics on clinical outcome.', Basic and Applied Histochemistry, vol. 30, no. 2, pp. 221-226.
Daidone MG, Silvestrini R, Ventura L, Coltro Campi C, Salvadori B, Bartoli C. Breast cancer: implications of tumor cell kinetics on clinical outcome. Basic and Applied Histochemistry. 1986;30(2):221-226.
Daidone, M. G. ; Silvestrini, R. ; Ventura, L. ; Coltro Campi, C. ; Salvadori, B. ; Bartoli, C. / Breast cancer : implications of tumor cell kinetics on clinical outcome. In: Basic and Applied Histochemistry. 1986 ; Vol. 30, No. 2. pp. 221-226.
@article{2fd4c2e220b045ad9bf6bba57d7e5bf9,
title = "Breast cancer: implications of tumor cell kinetics on clinical outcome.",
abstract = "The relevance of tumor proliferative activity as an indicator of biologic aggressiveness was analyzed on a series of 506 patients with primary breast cancer. In 258 patients with operable tumors without nodal and distant metastases, none of whom was subjected to postoperative irradiation or systemic adjuvant therapy, proliferative activity was significantly correlated with prognosis; 6-year relapse-free survival (RFS) and overall survival (OS) were higher for patients with slowly proliferating tumors for patient with fast-proliferating tumors (RFS: 80.5{\%} vs 59.6{\%}, p = 0.00004; OS: 90.8{\%} vs 74.4{\%}, p = 0.002). On a series of 196 patients with node-positive operable tumors, subjected to 6 or 12 cycles of cyclophosphamide, methotrexate and 5-fluorouracil, a trend in favor of longer 6-year RFS was observed for patients with slowly proliferating tumors than for patients with fast-proliferating tumors (62.5{\%} vs 48.3{\%}, p = 0.08), whereas proliferative activity did not influence OS. In 52 patients with locally advanced disease treated with a multimodality approach, including chemotherapy (adriamycin and vincristine), surgery or radiotherapy, tumor proliferative activity was a strong indicator of biologic aggressivity, since women with slowly proliferating cancers had a higher 4-year probability of OS than women with fast-proliferating tumors (68.1{\%} vs 36.7{\%}, p = 0.02).",
author = "Daidone, {M. G.} and R. Silvestrini and L. Ventura and {Coltro Campi}, C. and B. Salvadori and C. Bartoli",
year = "1986",
language = "English",
volume = "30",
pages = "221--226",
journal = "Basic and Applied Histochemistry",
issn = "0391-7258",
publisher = "Ermes",
number = "2",

}

TY - JOUR

T1 - Breast cancer

T2 - implications of tumor cell kinetics on clinical outcome.

AU - Daidone, M. G.

AU - Silvestrini, R.

AU - Ventura, L.

AU - Coltro Campi, C.

AU - Salvadori, B.

AU - Bartoli, C.

PY - 1986

Y1 - 1986

N2 - The relevance of tumor proliferative activity as an indicator of biologic aggressiveness was analyzed on a series of 506 patients with primary breast cancer. In 258 patients with operable tumors without nodal and distant metastases, none of whom was subjected to postoperative irradiation or systemic adjuvant therapy, proliferative activity was significantly correlated with prognosis; 6-year relapse-free survival (RFS) and overall survival (OS) were higher for patients with slowly proliferating tumors for patient with fast-proliferating tumors (RFS: 80.5% vs 59.6%, p = 0.00004; OS: 90.8% vs 74.4%, p = 0.002). On a series of 196 patients with node-positive operable tumors, subjected to 6 or 12 cycles of cyclophosphamide, methotrexate and 5-fluorouracil, a trend in favor of longer 6-year RFS was observed for patients with slowly proliferating tumors than for patients with fast-proliferating tumors (62.5% vs 48.3%, p = 0.08), whereas proliferative activity did not influence OS. In 52 patients with locally advanced disease treated with a multimodality approach, including chemotherapy (adriamycin and vincristine), surgery or radiotherapy, tumor proliferative activity was a strong indicator of biologic aggressivity, since women with slowly proliferating cancers had a higher 4-year probability of OS than women with fast-proliferating tumors (68.1% vs 36.7%, p = 0.02).

AB - The relevance of tumor proliferative activity as an indicator of biologic aggressiveness was analyzed on a series of 506 patients with primary breast cancer. In 258 patients with operable tumors without nodal and distant metastases, none of whom was subjected to postoperative irradiation or systemic adjuvant therapy, proliferative activity was significantly correlated with prognosis; 6-year relapse-free survival (RFS) and overall survival (OS) were higher for patients with slowly proliferating tumors for patient with fast-proliferating tumors (RFS: 80.5% vs 59.6%, p = 0.00004; OS: 90.8% vs 74.4%, p = 0.002). On a series of 196 patients with node-positive operable tumors, subjected to 6 or 12 cycles of cyclophosphamide, methotrexate and 5-fluorouracil, a trend in favor of longer 6-year RFS was observed for patients with slowly proliferating tumors than for patients with fast-proliferating tumors (62.5% vs 48.3%, p = 0.08), whereas proliferative activity did not influence OS. In 52 patients with locally advanced disease treated with a multimodality approach, including chemotherapy (adriamycin and vincristine), surgery or radiotherapy, tumor proliferative activity was a strong indicator of biologic aggressivity, since women with slowly proliferating cancers had a higher 4-year probability of OS than women with fast-proliferating tumors (68.1% vs 36.7%, p = 0.02).

UR - http://www.scopus.com/inward/record.url?scp=0022527876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022527876&partnerID=8YFLogxK

M3 - Article

C2 - 3741318

AN - SCOPUS:0022527876

VL - 30

SP - 221

EP - 226

JO - Basic and Applied Histochemistry

JF - Basic and Applied Histochemistry

SN - 0391-7258

IS - 2

ER -